Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Zevra Therapeutics (ZVRA) Accumulated Depreciation & Amortization (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization fell 36.55% year-over-year to $4.1 million, compared with a TTM value of $4.1 million through Dec 2025, down 36.55%, and an annual FY2025 reading of $4.1 million, down 36.55% over the prior year.
  • Accumulated Depreciation & Amortization was $4.1 million for Q4 2025 at Zevra Therapeutics, down from $6.4 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $6.4 million in Q4 2024 and bottomed at $1.4 million in Q4 2022.
  • Average Accumulated Depreciation & Amortization over 5 years is $3.1 million, with a median of $1.9 million recorded in 2021.
  • The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 291.0% in 2024, then tumbled 36.55% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.9 million in 2021, then fell by 25.04% to $1.4 million in 2022, then increased by 13.24% to $1.6 million in 2023, then surged by 291.0% to $6.4 million in 2024, then plummeted by 36.55% to $4.1 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ZVRA at $4.1 million in Q4 2025, $6.4 million in Q4 2024, and $1.6 million in Q4 2023.